Previous Close | 31.68 |
Open | 31.43 |
Bid | 28.82 x 900 |
Ask | 48.08 x 2900 |
Day's Range | 29.80 - 31.43 |
52 Week Range | 6.00 - 59.00 |
Volume | |
Avg. Volume | 10,980 |
Market Cap | 399.496M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.41 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for RGC
By Beth Senko, CFA NASDAQ:RGC Investors have faced challenging and volatile markets so far in 2022 as they sort through issues of inflation, supply chain disruption, continued covid issues, rising interest rates, and the disruption of the war in Ukraine. The S&P 500 has come close to bear market levels, down 19% in mid-June. Times of turbulence affect all stocks, large and small. It can be
By Beth Senko, CFA NASDAQ:RGC Founded in 2014, Hong Kong-based Regencell Bioscience (NASDAQ:RGC) is an early clinical stage bioscience company using Traditional Chinese Medicine (TCM) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases such as the coronavirus
HONG KONG, May 18, 2022--Regencell Bioscience Holdings Limited (NASDAQ: RGC):